QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Clinical trial NCT03127098 · TERMINATED
Trial details
- NCT number
- NCT03127098
- Sponsor
- NantCell, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-26
- Primary completion
- 2017-12-07
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.